CN101396363A - 一种含有阿巴芬净的复方抗菌药物组合物 - Google Patents
一种含有阿巴芬净的复方抗菌药物组合物 Download PDFInfo
- Publication number
- CN101396363A CN101396363A CNA2007100927760A CN200710092776A CN101396363A CN 101396363 A CN101396363 A CN 101396363A CN A2007100927760 A CNA2007100927760 A CN A2007100927760A CN 200710092776 A CN200710092776 A CN 200710092776A CN 101396363 A CN101396363 A CN 101396363A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- abafungin
- class
- clindamycin
- antibacterials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 title claims description 49
- 229950006373 abafungin Drugs 0.000 title claims description 49
- 239000000203 mixture Substances 0.000 title claims description 30
- 229940124350 antibacterial drug Drugs 0.000 title abstract description 5
- 239000002131 composite material Substances 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000031888 Mycoses Diseases 0.000 claims abstract description 10
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 42
- 230000000844 anti-bacterial effect Effects 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- -1 phenalgin sulfonamide Chemical class 0.000 claims description 24
- 241000233866 Fungi Species 0.000 claims description 23
- 208000003322 Coinfection Diseases 0.000 claims description 17
- 229940088710 antibiotic agent Drugs 0.000 claims description 15
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 15
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 claims description 14
- 229960002291 clindamycin phosphate Drugs 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 14
- 229960002227 clindamycin Drugs 0.000 claims description 12
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 9
- 229940097572 chloromycetin Drugs 0.000 claims description 9
- 229960002626 clarithromycin Drugs 0.000 claims description 9
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- 229960000282 metronidazole Drugs 0.000 claims description 8
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 150000003952 β-lactams Chemical class 0.000 claims description 5
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 4
- 108010001478 Bacitracin Proteins 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003071 bacitracin Drugs 0.000 claims description 4
- 229930184125 bacitracin Natural products 0.000 claims description 4
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004130 itraconazole Drugs 0.000 claims description 4
- 229960004125 ketoconazole Drugs 0.000 claims description 4
- 229960000667 mepartricin Drugs 0.000 claims description 4
- ALPPGSBMHVCELA-WHUUVLPESA-N methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-7-oxoheptan-2-yl]-1,3,5,7,9,13,37-heptahydroxy-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,7,9,13,37-heptahydroxy-17-[5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl]-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate Chemical compound CC1\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)OC1C(C)CCC(O)CC(=O)C1=CC=C(N)C=C1.C1=CC(NC)=CC=C1C(=O)CC(O)CCC(C)C1C(C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)O1 ALPPGSBMHVCELA-WHUUVLPESA-N 0.000 claims description 4
- 229960000988 nystatin Drugs 0.000 claims description 4
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 229960005053 tinidazole Drugs 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 3
- 229940126575 aminoglycoside Drugs 0.000 claims description 3
- 230000001857 anti-mycotic effect Effects 0.000 claims description 3
- 239000002543 antimycotic Substances 0.000 claims description 3
- 229960001200 clindamycin hydrochloride Drugs 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 150000007660 quinolones Chemical class 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 239000002511 suppository base Substances 0.000 claims description 3
- 229940040944 tetracyclines Drugs 0.000 claims description 3
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 claims description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 2
- HYSALCMXIKJFNX-UHFFFAOYSA-N 2-benzyl-3-methylpyridine Chemical compound CC1=CC=CN=C1CC1=CC=CC=C1 HYSALCMXIKJFNX-UHFFFAOYSA-N 0.000 claims description 2
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- LIRCDOVJWUGTMW-ZWNOBZJWSA-N Chloramphenicol succinate Chemical compound OC(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 LIRCDOVJWUGTMW-ZWNOBZJWSA-N 0.000 claims description 2
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical compound O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 claims description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
- NUAQIRUAZSJTAI-YRPZDAAMSA-N O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)CC(C)C)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)CC(C)C)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 NUAQIRUAZSJTAI-YRPZDAAMSA-N 0.000 claims description 2
- 239000004100 Oxytetracycline Substances 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 108010040201 Polymyxins Proteins 0.000 claims description 2
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
- VYWWNRMSAPEJLS-MDWYKHENSA-N Rokitamycin Chemical compound C1[C@](OC(=O)CC)(C)[C@@H](OC(=O)CCC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C VYWWNRMSAPEJLS-MDWYKHENSA-N 0.000 claims description 2
- 229930192786 Sisomicin Natural products 0.000 claims description 2
- 108010053950 Teicoplanin Proteins 0.000 claims description 2
- 108700029371 albomycin Proteins 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- BIDUPMYXGFNAEJ-APGVDKLISA-N astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 claims description 2
- 229950004074 astromicin Drugs 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 2
- 229960004357 chloramphenicol succinate Drugs 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- 229960002398 demeclocycline Drugs 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 claims description 2
- 229960003203 erythromycin estolate Drugs 0.000 claims description 2
- VEGXETMJINRLTH-ALRICIOSSA-N etimicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@H](O)[C@H]1O[C@@H]1[C@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N VEGXETMJINRLTH-ALRICIOSSA-N 0.000 claims description 2
- 229950009953 etimicin Drugs 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003923 gatifloxacin Drugs 0.000 claims description 2
- DNYGXMICFMACRA-UHFFFAOYSA-N gentamicin C1A Natural products O1C(CNC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N DNYGXMICFMACRA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002867 griseofulvin Drugs 0.000 claims description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004144 josamycin Drugs 0.000 claims description 2
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- 229930027917 kanamycin Natural products 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- 229940083668 ketek Drugs 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229950007634 kitasamycin Drugs 0.000 claims description 2
- XYJOGTQLTFNMQG-KJHBSLKPSA-N leucomycin V Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 XYJOGTQLTFNMQG-KJHBSLKPSA-N 0.000 claims description 2
- 229960005287 lincomycin Drugs 0.000 claims description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 2
- 229960003907 linezolid Drugs 0.000 claims description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 2
- 229960002422 lomefloxacin Drugs 0.000 claims description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 2
- 229940042016 methacycline Drugs 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960004744 micronomicin Drugs 0.000 claims description 2
- 229960002757 midecamycin Drugs 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 229940041009 monobactams Drugs 0.000 claims description 2
- 229960000808 netilmicin Drugs 0.000 claims description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- 108700014375 norvancomycin Proteins 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- 229960000625 oxytetracycline Drugs 0.000 claims description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
- 235000019366 oxytetracycline Nutrition 0.000 claims description 2
- 150000002960 penicillins Chemical class 0.000 claims description 2
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims description 2
- 229960001732 pipemidic acid Drugs 0.000 claims description 2
- 229940041153 polymyxins Drugs 0.000 claims description 2
- 229960003485 ribostamycin Drugs 0.000 claims description 2
- 229930190553 ribostamycin Natural products 0.000 claims description 2
- NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 claims description 2
- NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001170 rokitamycin Drugs 0.000 claims description 2
- 229960005224 roxithromycin Drugs 0.000 claims description 2
- 229960005456 sisomicin Drugs 0.000 claims description 2
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
- 229960000268 spectinomycin Drugs 0.000 claims description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 2
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 claims description 2
- 229950006796 spiramycin ii Drugs 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004306 sulfadiazine Drugs 0.000 claims description 2
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001608 teicoplanin Drugs 0.000 claims description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 238000011287 therapeutic dose Methods 0.000 claims description 2
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 claims description 2
- 229960003053 thiamphenicol Drugs 0.000 claims description 2
- 229960000707 tobramycin Drugs 0.000 claims description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
- 229950008187 tosufloxacin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 210000004877 mucosa Anatomy 0.000 abstract description 6
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 108010020326 Caspofungin Proteins 0.000 abstract 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 abstract 2
- 229960003034 caspofungin Drugs 0.000 abstract 2
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 36
- 238000003756 stirring Methods 0.000 description 23
- 239000003814 drug Substances 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 235000011187 glycerol Nutrition 0.000 description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 229940099259 vaseline Drugs 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940075507 glyceryl monostearate Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 6
- 235000010262 sodium metabisulphite Nutrition 0.000 description 6
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
- 229960003415 propylparaben Drugs 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 241000259759 Cassida nobilis Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960002179 ephedrine Drugs 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 206010040872 skin infection Diseases 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 235000010199 sorbic acid Nutrition 0.000 description 4
- 239000004334 sorbic acid Substances 0.000 description 4
- 229940075582 sorbic acid Drugs 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 3
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical class CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 206010005913 Body tinea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 244000173166 Pyrus ussuriensis Species 0.000 description 2
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 201000003875 tinea corporis Diseases 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
- 235000010244 calcium sorbate Nutrition 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004714 clindamycin palmitate Drugs 0.000 description 1
- OYSKUZDIHNKWLV-PRUAPSLNSA-N clindamycin palmitate Chemical compound O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 OYSKUZDIHNKWLV-PRUAPSLNSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229950005770 hyprolose Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种治疗真菌感染或细菌与真菌混合感染的含有阿巴芬净的皮肤外用和粘膜给药的复方药物组合物,该组合物含有阿巴芬净0.1~10%;至少另一种抗菌药物0.01~10%和药用辅料。该组合物特别适用于真菌和细菌混合感染的患者的治疗。
Description
技术领域:
本发明属制剂领域,具体涉及一种含有阿巴芬净和其它抗菌药物的药物组合物,该药物组合物用于治疗真菌感染或细菌、真菌混合感染。
背景技术:
浅部真菌病是一种常见病,其传染性强,发病率极高、顽固而又极易复发,如足癣,即脚气,全国平均发病率达三分之一,在一些高发地区发病率高达60%。皮肤细菌感染可分为原发性或继发性。原发性感染常有特征性的形态和病程,开始由单一病原菌引起,发生在正常皮肤上,通常葡萄球菌易引起脓疱疮、毛囊炎、疖、痈等,链球菌易引起丹毒及蜂窝织炎,诱发肾炎及关节炎等;继发性感染常发生在已有病变的皮肤上,见于特殊部位(如外耳)或特定类型的皮损(如溃疡),常由革兰阴性菌(变形杆菌、假单胞菌、大肠杆菌)所致。皮肤细菌感染的病因自40年代以来,随着抗生素的迅速发展和广泛使用,使细菌性感染的治疗取得了很大进展,但由于耐药菌株尤其是多种耐药菌的出现和迅速传播,使感染性疾病的死亡率仍占相当高的比率,而皮肤真菌和细菌混合感染治疗情况,比单独感染真菌或细菌更加复杂,很多真菌感染都伴有细菌感染,发病率也相当高,因此,皮肤真菌和细菌混合感染的治疗仍是目前热门之一。
虽然目前抗真菌药物品种较多,但这些药物抗真菌作用均为单一作用机制,而且这些机制均在真菌生长时才发挥作用,对静止期的真菌效果较差。并且治愈率低,易复发。阿巴芬净(abafungin)为氨基噻唑类抗真菌药,其特征是对生长中和静止中的真菌细胞均具有杀灭作用,具有抑制真菌和杀灭真菌的双重作用,能靶向静止的真菌细胞,有效杜绝感染复发。该药是具有这种作用机制的第一个药物。其抗菌谱广,可以治疗一些真菌和细菌的混合感染;但单一组分对于治疗和预防皮肤、粘膜真菌以及细菌混合感染效果并不理想。如果其他类抗菌药物与阿巴芬净制成组合物,可治疗一些细菌、真菌混合感染,对混合感染具有明显的协同作用。
目前关于阿巴芬净制剂,WO2005034956(申请日:2004.1.24;公开日:2005.4.21),介绍了一种阿巴芬净的指甲油制剂,用于治疗指甲真菌。
CN1969874(申请日:2006.12.07;公开日:2007.05.30),介绍了一种外用复方阿巴芬净药物组合物,阿巴芬净与肾上腺皮质激素的复方组合物。
目前尚无含阿巴芬净与其他抗菌药物的组合物,并能有效治疗皮肤和粘膜真菌、真菌和细菌混合感染的文献报道。
发明内容:
本发明的目的是提供一种治疗真菌感染或真菌混合感染的药物组合物,尤其提供一种治疗皮肤和粘膜真菌或真菌与细菌混合感染的复方阿巴芬净药物组合物。对治疗皮肤和粘膜真菌或混合感染达到增效或协同作用,克服上述单一组分不能有效治疗真菌和细菌二者混合感染引起的疾病的特点。
本发明中所述的复方阿巴芬净药物组合物包含有效治疗量的阿巴芬净或其可药用盐,至少另一种抗菌药物0.01~10%(重量)和药用辅料;其中,阿巴芬净或其可药用盐占组合物重量的0.1~10%,优选0.5~5%,更优选1~2%;另一种抗菌药物占组合物重量的0.01~8%,优选0.01~6%,更优选0.05~4%。
上述的所说的另一种抗菌药物,包括1.β-内酰胺类:青霉素类、头霉素类、单环β-内酰胺类、碳氢霉烯类、β-内酰胺霉抑制剂、头孢菌素类;2.氨基糖苷类:链霉素、大观霉素、庆大霉素、卡那霉素、阿米卡星、妥布霉素、核糖霉素、西索米星、奈替米星、小诺米星、依帕米星、依替米星、阿司米星等;3.大环内酯类:红霉素、琥乙霉素、克拉霉素(甲红霉素)、依托红霉素、白霉素、克林霉素磷酸酯、麦迪霉素、交沙霉素、乙酰螺旋霉素、罗红霉素、甲红霉素、阿齐霉素、罗他霉素、吉他霉素、泰利霉素等;4.多肽类:多粘菌素类、杆菌肽、粘菌肽、万古霉素等.5.四环素类:四环素、土霉素、多西环素(脱氧土霉素)、米诺环素、美他环素、地美环素等;6.多烯类:制霉菌素、二性霉素B、美帕曲星等;7.芳香族类(含酰胺酮类):氯霉素、甲砜霉素(硫霉素)等;8.喹诺酮类:吡哌酸、诺氟沙星、氧氟沙星、环丙沙星、洛美沙星、加替沙星、托氟沙星等;9.磺胺类(均含氨苯磺酰胺):磺胺嘧啶、磺胺异恶唑、磺胺甲恶唑、甲苄啶(TMP)等;10.恶唑酮类:利奈唑胺等;11.糖肽类:去甲万古霉素、替考拉宁、达巴万里等;12.氯霉素类:氯霉素、琥珀氯霉素等;13.林可酰胺类:林可霉素、克林霉素、盐酸克林霉素和磷酸克林霉素(或克林霉素磷酸酯)等;14.硝咪唑类:替硝唑、甲硝唑等;15.抗真菌类:灰黄霉素、克念菌素、克霉唑、酮康唑、咪康唑、氟康唑、伊曲康唑、美帕曲星、特比萘芬等.
上述所说的另一种抗菌药物优选克林霉素或其盐,如盐酸克林霉素、磷酸克林霉素(克林霉素磷酸酯)和克林霉素棕榈酸酯。
本发明所述组合物的制剂形式为乳膏剂、凝胶剂、栓剂、油剂、乳剂、洗剂、喷剂、滴丸剂、软胶囊剂、霜剂等在内的所有外用和粘膜给药制剂。
本发明所述的含有阿巴芬净药物组合物,还进一步包括药用辅料或载体,该辅料或载体包括油性基质4~45%、水溶性基质0~10%、凝胶基质4~35%、防腐剂0~1%、抗氧剂0~1%和蒸馏水,根据具体制剂形式的需要可选择其中的二种或二种以上(多种)。如制剂形式为乳膏剂可选择油性基质4~45%、水溶性基质0~10%、防腐剂0~1%、抗氧剂0~1%和蒸馏水;为凝胶剂时可选择凝胶基质4~35%、防腐剂0~1%、抗氧剂0~1%和蒸馏水;为栓剂时可选择栓剂基质4~35%防腐剂0~1%、抗氧剂0~1%和蒸馏水;如需要,还可还包括保湿剂,如甘油、甲基葡萄糖苷醚、丙二醇等。
上述所说的油溶性基质包括凡士林、羊毛酯、液体石蜡、硬脂酸、单硬脂酸甘油酯、蜂蜡、鲸蜡醇、硬脂醇、十六醇、十八醇、吐温—80、乙酰化单甘油酯在内的任一种或多种。
上述所说的水溶性基质包括聚乙二醇类、硅酸镁铝、乙二胺四乙酸、三乙醇胺、纤维素衍生物、泊洛沙姆、聚氯乙烯硬脂酸酯、聚丙烯酸、甘油在内的任一种或多种。
上述所说的凝胶基质包括卡波姆、羟丙纤维素、硅酸镁铝、海藻酸钠、透明质酸、交联聚丙烯酸树脂、SDB-L-400、西黄耆胶、纤维素衍生物、丙二醇、乙醇、明胶在内的一种或多种。
上述所说的栓剂基质包括可可豆酯、脂肪酸甘油酯、甘油明胶、S—40、聚乙二醇、泊洛沙姆、聚氧乙烯(40)单硬脂酸甘油酯在内的一种或多种。
上述所说的防腐剂包括尼泊金甲酯、尼泊金乙酯、尼泊金丙酯、尼泊金丁酯、苯甲酸、苯甲酸钠、山梨酸、山梨酸钾、山梨酸钙、葡萄糖酸洗必泰、苯扎溴铵、苯扎氯铵在内的任一种、两种或任两种以上。
上述所说的抗氧剂包括亚硫酸钠、焦亚硫酸钠、二叔丁羟基甲苯、亚硫酸氢钠、硫代硫酸钠在内的任一种、两种或任两种以上。
本发明具体提供了一种阿巴芬净的复方抗菌药物组合物,包含阿巴芬净、克林霉素和药用辅料,所说的克林霉素为盐酸克林霉素和磷酸克林霉素,优先磷酸克林霉素(或称克林霉素磷酸酯),其制剂形式为凝胶剂。
本发明所述的含阿巴芬净的复方抗菌组合物,可用于治疗真菌感染或真菌与细菌混合感染混合感染。
具体实施方式
以下结合实施例对本发明做详细描述,但不限制本发明的范围。
实施例1
配方(乳膏剂):(1)阿巴芬净10g、(2)制霉菌素4g、(3)凡士林10g、(4)硬脂酸110g、(5)液体石蜡60g、(6)单硬脂酸甘油酯35g、(7)尼泊金丙酯0.2g、(8)十八醇50g、(9)三乙醇胺4.5g、(10)尼泊金甲酯1.8g、(11)二叔丁羟基甲苯2g、(12)甘油40g、(13)焦亚硫酸钠10g、(14)乙二胺四乙酸1g、(15)加蒸馏水至1000g。
制备方法:先将甘油、焦亚硫酸钠放入研钵里研磨均匀后,加入阿巴芬净和制霉菌素,研匀此为①;将凡士林、硬脂酸、单硬脂酸甘油酯、十八醇、液体石蜡、尼泊金丙酯混合,置于水浴70~80℃搅拌并使溶解,此为②;将尼泊金甲酯、二叔丁羟基甲苯、乙二胺四乙酸、水混合,置于水浴70~80℃搅拌并使溶解,此为③;将①加入到③中,边加边搅拌,再将②加入,搅拌至乳化完全,待冷却后,装量即可。
实施例2
配方(乳膏剂):(1)阿巴芬净15g、(2)甲硝唑0.5g、(3)羊毛酯45g、(4)乙酰化单甘油酯70g、(5)液体石蜡60g、(6)十六醇80g、(7)葡萄糖酸洗必泰0.06g、(8)亚硫酸钠2g、(9)硅酸镁铝35g、(10)加蒸馏水至1000g。
制备方法:先将羊毛酯、乙酰化单甘油酯、液体石蜡、十六醇混合,置于水浴65~75℃搅拌并使溶解,此为①;将葡萄糖酸洗必泰、亚硫酸钠、硅酸镁铝、蒸馏水置于水浴70~80℃搅拌并使溶解,此为②;边搅拌②边加入①,备用;阿巴芬净、甲硝唑混合,此为③;将上述③等量递加到①②混合基质中,混合均匀,装量,即得。
实施例3
配方(栓剂):(1)阿巴芬净2.5g、(2)克拉霉素1.5g、(3)甘油明胶520g、(4)凡士林60g、(5)三乙醇胺20g、(6)十二烷基硫酸钠1g、(7)尼波金甲酯1g、(8)尼泊金丙酯1g、(9)加蒸馏水至1000g
制备方法:将甘油明胶和蒸馏水混合,并置于水浴50~60℃中,搅拌,溶解此为①;将凡士林置于水浴50~60℃中,溶解此为②;待①、②溶解完后,将②到入①中,搅拌均匀;将阿巴芬净与克拉霉素、三乙醇胺、尼泊金甲酯、尼泊金丙酯和十二烷基硫酸钠混合均匀后,加入到①②混合物里,搅拌均匀后,放冷,接近凝固时,倒入适宜的阴道栓模具中,稍溢出,冷却凝固后刮平,取出包装即得。
实施例4
配方(栓剂):(1)阿巴芬净18g、(2)甲硝唑1.0g、(3)伊曲康唑1.5g、(4)S—40500g、(5)尼泊金乙酯1.6g、(6)十二烷基硫酸钠1g、(7)加蒸馏水至1000g
制备方法:取S—40、十二烷基硫酸钠、尼泊金乙酯、蒸馏水混匀溶液在水浴上熔化,加入阿巴芬净、甲硝唑、伊曲康唑,混匀;接近凝固时,灌模,取出,包装即得。
实施例5
配方(凝胶剂):(1)阿巴芬净20g、(2)克林霉素磷酸酯1g、(3)丙二醇800g、(4)苯甲酸2g、(5)明胶20g、(6)加蒸馏水至1000g。
制备方法:取明胶,加水适量,40℃水浴,浸泡至充分溶胀成凝胶,备用。取阿巴芬净、克林霉素磷酸酯和苯甲酸,加入丙二醇,搅拌均匀;搅拌下将凝胶加入到药液中,不断均质,至搅匀,加水至1000g;搅拌均匀,装量,即得。
实施例6
配方(凝胶剂):(1)阿巴芬净1.0g、(2)万古霉素2.5g、(3)甲硝唑1.5g、(4)脂肪酸山梨坦1g、(5)海藻酸钠(或透明质酸)30g、(6)丙二醇485g、(7)苯扎氯铵0.01g、(8)加蒸馏水至1000g
制备方法:取海藻酸钠(或透明质酸)、丙二醇置于水浴50~60℃中,边搅拌边逐渐加入2—吡咯酮;另取阿巴芬净、万古霉素、甲硝唑、脂肪酸山梨坦、尼波金甲酯、乙酯、蒸馏水搅拌混匀,再搅拌混合;即得透明凝胶,放冷,装量,即可。
实施例7
配方(霜剂):(1)阿巴芬净40g、(2)克林霉素10g、(3)甘油100g、(4)十八醇40g、(5)单硬脂酸甘油酯35g、(6)凡士林100g、(7)吐温—8020g、(8)苯甲酸钠0.15g、(9)二叔丁羟基甲苯1.8g、(10)加蒸馏水至1000g。
制备方法:先将十八醇、单硬脂酸甘油酯、凡士林、吐温—80混合,置于水浴70~80℃搅拌并使溶解,为①;苯甲酸钠、二叔丁羟基甲苯、加蒸馏水混合,置于水浴70~80℃搅拌并使溶解,为②;边搅拌②边加入①;将阿巴芬净、克林霉素、甘油混合均匀,此为③,再将上述①②混合物等量递加到③里,混合均匀,装量,即得。
实施例8
配方(油剂):(1)阿巴芬净10g、(2)氯霉素1.5g、(3)甲基葡萄糖苷醚-10500g、(4)乙醇200g、(5)苯甲酸0.08g、(6)加硬脂酸至1000g。
制备方法:将阿巴芬净与氯霉素、甲基葡萄糖苷醚-10、苯甲酸、硬脂酸混合均匀后,置于水浴70~80℃搅拌并使溶解后,加入乙醇混匀,搅拌混合,装量,即得。
实施例9
配方(喷剂):(1)阿巴芬净1g、(2)甲红霉素9.5g、(3)甲基葡萄糖苷醚—20200g、(4)山梨酸0.3g、(5)乙醇200g、(6)加蒸馏水至1000g。
制备方法:将阿巴芬净与甲红霉素、山梨酸、甲基葡萄糖苷醚—20混合均匀,再加入乙醇、蒸馏水混合均匀,搅拌均匀,装量,即得。
实施例10
配方(洗剂):(1)阿巴芬净2g、(2)替硝唑2g、(3)甘油100g、(4)尼波金乙酯0.3g、(5)加蒸馏水至1000g
制备方法:将阿巴芬净与替硝唑、尼波金乙酯、甘油混合均匀,再加入蒸馏水混合均匀,搅拌均匀,装量,即得。
实施例11
配方(滴丸剂):(1)阿巴芬净0.8g、(2)克林霉素4.5g、(3)酮康唑1g、(4)吐温—8050g、(5)尼波金甲酯0.2g、(6)焦亚硫酸钠2g、(7)蒸馏水适量、(8)乙醇适量、(9)PEG至1000g、(10)冷却液适量。
制备方法:将阿巴芬净与克林霉素、酮康唑加水和吐温—80混合,煎煮,浓缩,放冷;加乙醇至浓缩液的醇含量达到一定量,搅拌,静置,过滤,回收乙醇至无醇味,浓缩至浸膏,制得干提取物;再将干提取物、尼波金甲酯加入到熔化后的PEG中,适当温度保温,用滴管滴入冷却液中,滴速适当,收集滴丸,吸干冷却液即得。
实施例12
配方(软胶囊剂):(1)阿巴芬净15g、(2)杆菌肽2g、(3)明胶80、(4)甘油280g、(5)硅酸铝镁10g、(6)山梨酸0.2g、(7)焦亚硫酸钠2g、(8)吐温—8035g、(9)蒸馏水至1000g
制备方法:将明胶和蒸馏水,水浴加热溶解后,加入甘油、防腐剂,搅拌均匀后保温静置备用;将硅酸铝镁加入到吐温—80中,再将阿巴芬净和杆菌肽与之混合均匀,再加入焦亚硫酸钠,搅拌均匀,最后加入上述备用的混合物,混合均匀,用胶体磨石法粉碎,过筛,制得混悬液;将上述混悬液移入滴制机中,制得软胶囊,装量,即可。
实施例13
药效研究
1.对豚鼠皮肤真菌和细菌合并感染的抑制作用
药物:用实施例5的配方制得制剂1;用实施例5的方法制得阿巴芬净的单方制剂2;用实
施例5的方法制得克林霉素磷酸酯的单方制剂3;
菌种:真菌(须毛癣菌)和细菌(金黄色葡萄球菌)两种菌新鲜培养物的混悬菌液。
实验动物:豚鼠,250-300g,雄性,重庆中药研究院实验动物中心提供,合格证号:SCXK(渝)20020004。
豚鼠40只双后足和背部左右两侧约3×3cm2剃毛,用砂纸反复磨擦豚鼠去毛皮肤,以皮肤有渗出液但又不出血为准,用玻棒将制备的菌种混悬液105/mL涂擦于损伤皮肤,每1cm2接种1mL。室温保持30C°,10d后动物接种真菌处皮肤出现红斑、红肿、皮疹、鳞屑或痂皮。将合并感染须毛癣菌和金葡球菌的豚鼠随机分为4组,分别为制剂1组、制剂2组,制剂3组、生理盐水阴性对照组,每组10只。各组动物背部皮肤感染区每日涂抹用药1次,每次30min,共7d。对治疗前后皮肤感染症状进行评分,0分表示无皮肤损害,1分为点状红斑,2分为全范围红斑,3分为红肿、鳞屑,4分为超过范围的红斑、结痂。
结果:
治疗前后豚鼠须癣毛癣菌、金黄色葡萄球菌合并感染足癣、体癣皮肤感染变化情况评分,统计分析显示各组药前无差异;药后与药前相比各组均有显著性差异;对照组评分显著加重(P<0.05),各治疗组评分均有减轻(P<0.05),药后制剂1组、制剂2组和制剂3组与对照组相比有显著性差异(P<0.05);药后制剂1组、制剂2组和制剂3组相比有显著性差异(P<0.05)。结果提示,制剂1组、制剂2组和制剂3组治疗豚鼠须毛癣菌、金黄色葡萄球菌合并感染足癣、体癣有很好治疗作用,并且制剂1的疗效显著优于阿巴芬净的单方制剂2及克林霉素的单方制剂3(见表1)
表1 各种制剂对须癣毛癣豚鼠体表感染治疗作用
注:与对照组比:*P<0.05,制剂1组、制剂2组和制剂3组比较:ΔP<0.05
从上表1的结果可以看出,阿巴芬净与其它抗菌素联用具有协同作用。
2 体外抗菌活性试验
目的:考察本发明对革兰氏阳性菌和霉菌的体外抗菌活性。
受试药:按实施例5制备的阿巴芬净与克林霉素磷酸酯的复方制剂。
阳性对照药1:阿巴芬净。
阳性对照药2:克林霉素磷酸酯。
培养基:M-H肉汤培养基+5%马血、血琼脂培养基、真菌培养基。
菌种:临床分离菌株:金黄色葡萄球菌(MRSA和MSSA)—15株、表皮葡萄球菌Se—1株、肺炎链球菌S—11株、肺炎克雷伯菌K—14株、绿脓杆菌P—12株、链球菌—9株、白色念珠菌C—11株等73株(共7种)菌株均来源于重庆第三军医大学附属西南医院检验科微生物室。
抗菌活性MIC和MBC的测定方法
用相应的液体培养基将受试药物稀释成1:2.5、1:5、1:10、1:20、1:40、1:80、1:160、1:320的系列含药培养基(白色念珠菌受试药物稀释成1:1.25、1:2.5、1:5、1:10、1:20、1:40、1:80、1:160、1:320系列浓度),分装灭菌小试管,每管1ml,再分别接种0.1ml供试菌液,培养24小时,观察混浊程度,清澈透亮无菌生长的为最低药物浓度MIC,并同时计算MIC50和MIC90或GMIC。再取各管培养物划线接种于相应的固体培养基上,按照不同的菌种分别培养24-72小时,观察菌落生长情况,以平皿上菌落数<5个的最小稀释度的药物浓度为该药的最低杀菌浓度即MBC。
结果
根据试验结果可得出实施例5在试验浓度范围内对各种菌株均有效,相应的MIC、MBC总结见下表:
表2 实施例5体外抗菌活性试验结果(试管法)
结果:
体外受试药物实施例5的药品对金黄色葡萄球菌、表皮葡萄球菌、肺炎链球菌、肺炎克雷伯菌、绿脓杆菌和白色念珠菌等73株菌种均有不同程度的抑菌作用。对革兰氏阳性菌和霉菌有一定的杀菌作用,起效较快、作用较强,其抗菌作用强于各自单用的效果。
结论:
本发明通过各组分的协同作用,可增强各抗菌药物的特有疗效,对于各种感染原,尤其是真菌和细菌混合感染的抗菌效果明显优于目前常用的抗菌药物的单药组分的抗菌效果。从而解决了传统抗菌药物治疗范围狭窄、治疗不彻底和易复发等缺点,成为新型的高效抗菌药物。
Claims (20)
1、一种治疗真菌感染或真菌混合感染的药物组合物,包含有效治疗量的阿巴芬净或其可药用盐0.1~10%(重量),至少另一种抗菌药物0.01~10%(重量)和药用辅料。
2、如权利要求1所述的药物组合物,所说的另一种抗菌药物,包括β-内酰胺类、氨基糖苷类、大环内酯类、多肽类、四环素类、多烯类、芳香族类(含酰胺酮类)、喹诺酮类、磺胺类(均含氨苯磺酰胺)、恶唑酮类、糖肽类、氯霉素类、林可酰胺类、硝咪唑类或抗真菌类。
3、如权利要求2所述的药物组合物,所述的β-内酰胺类包括青霉素类、头霉素类、单环β-内酰胺类、碳氢霉烯类、β-内酰胺霉抑制剂、或头孢菌素类。
4、如权利要求2所述的药物组合物,所述的氨基糖苷类包括链霉素、大观霉素、庆大霉素、卡那霉素、阿米卡星、妥布霉素、核糖霉素、西索米星、奈替米星、小诺米星、依帕米星、依替米星或阿司米星。
5、如权利要求2所述的抗菌药物,所述的大环内酯类包括红霉素、琥乙霉素、克拉霉素、依托红霉素、白霉素、麦迪霉素、交沙霉素、乙酰螺旋霉素、罗红霉素、甲红霉素、阿齐霉素、罗他霉素、吉他霉素、泰利霉素。
6、如权利要求2所述的药物组合物,所述的多肽类包括多粘菌素类、杆菌肽、粘菌肽、万古霉素。
7、如权利要求2所述的药物组合物,所述的四环素类包括四环素、土霉素、多西环素、米诺环素、美他环素、地美环素。
8、如权利要求2所述的药物组合物,所述的多烯类包括制霉菌素、二性霉素B、美帕曲星。
9、如权利要求2所述的药物组合物,所述的芳香族类包括氯霉素、甲砜霉素。
10、如权利要求2所述的药物组合物,所述的喹诺酮类包括吡哌酸、诺氟沙星、氧氟沙星、环丙沙星、洛美沙星、加替沙星、托氟沙星。
11、如权利要求2所述的药物组合物,所述的磺胺类包括磺胺嘧啶、磺胺异恶唑、磺胺甲恶唑、甲苄啶。
12、如权利要求2所述的药物组合物,所述的恶唑酮类为利奈唑胺。
13、如权利要求2所述的药物组合物,所述的糖肽类包括去甲万古霉素、替考拉宁、达巴万里。
14、如权利要求2所述的药物组合物,所述的氯霉素类包括氯霉素、琥珀氯霉素。
15、如权利要求2所述的抗菌药物,所述的林可酰胺类包括林可霉素、克林霉素或其药用盐或酯。
16、如权利要求2所述的药物组合物,所述的硝咪唑类包括替硝唑、甲硝唑。
17、如权利要求2所述的药物组合物,所述的抗真菌类包括灰黄霉素、克念菌素、克霉唑、酮康唑、咪康唑、氟康唑、伊曲康唑、美帕曲星、特比萘芬。
18、权利要求1所述的药物组合物,所说的药用辅料选自油性基质、水溶性基质、凝胶基质、栓剂基质、防腐剂、抗氧剂和蒸馏水中的至少一种。
19、权利要求15所述的药物组合物,所述的克林霉素的药用盐或酯为盐酸克林霉素和克林霉素磷酸酯。
20、权利要求1-19任一项所述的组合物,其特征在于:该组合物的制剂形式为乳膏剂、凝胶剂、栓剂、油剂、乳剂、洗剂、喷剂、滴丸剂、软胶囊剂、霜剂、泡腾剂。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100927760A CN101396363A (zh) | 2007-09-28 | 2007-09-28 | 一种含有阿巴芬净的复方抗菌药物组合物 |
PCT/CN2008/072566 WO2009043307A1 (fr) | 2007-09-28 | 2008-09-27 | Composition médicale renfermant de l'abafungine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100927760A CN101396363A (zh) | 2007-09-28 | 2007-09-28 | 一种含有阿巴芬净的复方抗菌药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101396363A true CN101396363A (zh) | 2009-04-01 |
Family
ID=40515364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007100927760A Pending CN101396363A (zh) | 2007-09-28 | 2007-09-28 | 一种含有阿巴芬净的复方抗菌药物组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101396363A (zh) |
WO (1) | WO2009043307A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926758A (zh) * | 2009-06-23 | 2010-12-29 | 北京星昊医药股份有限公司 | 伊曲康唑栓剂 |
CN102626415A (zh) * | 2012-03-21 | 2012-08-08 | 山东省千佛山医院 | 四环素类药物联合应用氟康唑在制备抗真菌产品中的应用及其产品 |
CN104628163A (zh) * | 2013-11-11 | 2015-05-20 | 中国石油化工股份有限公司 | 一种杀菌缓蚀剂用组合物及其应用 |
CN104622871A (zh) * | 2015-01-21 | 2015-05-20 | 四川大学 | 一种恶唑酮类化合物作为变异链球菌生物膜抑制剂的应用 |
CN104888222A (zh) * | 2015-06-09 | 2015-09-09 | 深圳市健元医药科技有限公司 | 治疗复合感染的药物组合物及其制备方法 |
CN107296812A (zh) * | 2017-07-17 | 2017-10-27 | 赵云 | 运用头孢根治足癣/脚气的方法 |
CN109172591A (zh) * | 2018-11-22 | 2019-01-11 | 苏州纳工坊健康科技有限公司 | 一种杀菌随身喷中杀菌剂的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4445785A1 (de) * | 1994-12-21 | 1996-06-27 | Bayer Ag | Thermodynamisch stabile Form von N-[4-[2-(2,4-Dimethylphenoxy)-phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-2-pyrimidinamin (DTTP) |
DE10341944A1 (de) * | 2003-09-11 | 2005-04-28 | York Pharma Plc | Antimykotisch wirksame Nagellackformulierung mit substituierten 2-Aminothiazolen als Wirkstoff |
CN1969874B (zh) * | 2006-12-07 | 2011-06-15 | 重庆医药工业研究院有限责任公司 | 一种外用复方阿巴芬净药物组合物 |
-
2007
- 2007-09-28 CN CNA2007100927760A patent/CN101396363A/zh active Pending
-
2008
- 2008-09-27 WO PCT/CN2008/072566 patent/WO2009043307A1/zh active Application Filing
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101926758A (zh) * | 2009-06-23 | 2010-12-29 | 北京星昊医药股份有限公司 | 伊曲康唑栓剂 |
CN102626415A (zh) * | 2012-03-21 | 2012-08-08 | 山东省千佛山医院 | 四环素类药物联合应用氟康唑在制备抗真菌产品中的应用及其产品 |
CN102626415B (zh) * | 2012-03-21 | 2014-08-06 | 山东省千佛山医院 | 四环素类药物联合应用氟康唑在制备抗真菌产品中的应用及其产品 |
CN104628163A (zh) * | 2013-11-11 | 2015-05-20 | 中国石油化工股份有限公司 | 一种杀菌缓蚀剂用组合物及其应用 |
CN104628163B (zh) * | 2013-11-11 | 2016-05-25 | 中国石油化工股份有限公司 | 一种杀菌缓蚀剂用组合物及其应用 |
CN104622871A (zh) * | 2015-01-21 | 2015-05-20 | 四川大学 | 一种恶唑酮类化合物作为变异链球菌生物膜抑制剂的应用 |
CN104622871B (zh) * | 2015-01-21 | 2016-08-17 | 四川大学 | 一种恶唑酮类化合物作为变异链球菌生物膜抑制剂的应用 |
CN104888222A (zh) * | 2015-06-09 | 2015-09-09 | 深圳市健元医药科技有限公司 | 治疗复合感染的药物组合物及其制备方法 |
CN107296812A (zh) * | 2017-07-17 | 2017-10-27 | 赵云 | 运用头孢根治足癣/脚气的方法 |
CN109172591A (zh) * | 2018-11-22 | 2019-01-11 | 苏州纳工坊健康科技有限公司 | 一种杀菌随身喷中杀菌剂的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2009043307A1 (fr) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101396363A (zh) | 一种含有阿巴芬净的复方抗菌药物组合物 | |
CN101014323B (zh) | 递药用磷脂凝胶组合物及用其治疗病症的方法 | |
US20030017207A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
US9314482B2 (en) | Methods and compositions for promoting wound healing | |
JP2009500336A (ja) | 局所用皮膚治療組成物 | |
CN101175474A (zh) | 降低微生物污染的方法 | |
JP2002514220A (ja) | 熱傷処置および感染防止のための局部スプレー | |
US20090280069A1 (en) | Proguanil to treat skin/mucosal diseases | |
RU2667974C2 (ru) | Фармацевтическая комбинированная композиция для местного и наружного применения на основе диоксидина | |
RU2536264C2 (ru) | Композиция для наружного применения на коже, содержащая соль и сахар в качестве активных ингредиентов, для предотвращения и лечения вагиноза, и ее применение | |
CN110753549A (zh) | 双磷脂素凝胶制剂及其用途 | |
RU2291694C2 (ru) | Фармацевтическая композиция, содержащая фунгицид, бактериостатический сульфонамид и антибактериальное соединение для местного применения | |
RU2655808C2 (ru) | Фармацевтическая комбинированная композиция для местного и наружного применения на основе бактериолитического и протеолитического комплекса ферментов | |
JP7378409B2 (ja) | 皮膚および粘膜感染症の局所治療用エマルション | |
Fthenakis | Field evaluation of flunixin meglumine in the supportive treatment of ovine mastitis. | |
WO2014205159A1 (en) | Poloxamer based inhalation composition | |
RU2698820C1 (ru) | Препарат для лечения мастита у коров в период лактации | |
Mishra et al. | Topical antibiotics and semisolid dosage forms | |
JP2003246726A (ja) | 抗菌組成物 | |
RU2367456C2 (ru) | Фармацевтическая композиция для местного применения, обладающая антибактериальным и некролитическим действием | |
RU2367455C2 (ru) | Фармацевтическая композиция для наружного и местного применения, обладающая антибактериальным и некролитическим действием | |
US20240058366A1 (en) | Methods of treating mastitis with an orthosomycin antimicrobial compound | |
RU2639129C1 (ru) | Препарат для лечения и/или профилактики инфекционно-воспалительных заболеваний | |
RU2367457C2 (ru) | Фармацевтическая композиция для наружного и местного применения, обладающая антибактериальным и некролитическим действием, на основе лизоамидазы | |
RU2180559C1 (ru) | Препарат для лечения мастита у животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090401 |